vs
Orthofix Medical Inc.（OFIX）与WORKIVA INC（WK）财务数据对比。点击上方公司名可切换其他公司
WORKIVA INC的季度营收约是Orthofix Medical Inc.的1.1倍（$247.3M vs $219.9M），WORKIVA INC净利率更高（7.7% vs -1.0%，领先8.7%），WORKIVA INC同比增速更快（19.9% vs 2.0%），WORKIVA INC自由现金流更多（$25.7M vs $16.8M），过去两年WORKIVA INC的营收复合增速更高（18.0% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Workiva Inc.是一家全球知名的SaaS企业，主打云原生关联报告合规平台，支持关联数据调用与报告流程自动化，可广泛应用于财务、会计、风险及合规等多个业务场景，助力企业提升运营效率与合规管理水平。
OFIX vs WK — 直观对比
营收规模更大
WK
是对方的1.1倍
$219.9M
营收增速更快
WK
高出17.9%
2.0%
净利率更高
WK
高出8.7%
-1.0%
自由现金流更多
WK
多$8.9M
$16.8M
两年增速更快
WK
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $247.3M |
| 净利润 | $-2.2M | $19.0M |
| 毛利率 | 71.1% | 80.4% |
| 营业利润率 | 0.2% | 25.8% |
| 净利率 | -1.0% | 7.7% |
| 营收同比 | 2.0% | 19.9% |
| 净利润同比 | 92.4% | — |
| 每股收益（稀释后） | $-0.05 | $0.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXWK
| Q1 26 | — | $247.3M | ||
| Q4 25 | $219.9M | $238.9M | ||
| Q3 25 | $205.6M | $224.2M | ||
| Q2 25 | $203.1M | $215.2M | ||
| Q1 25 | $193.6M | $206.3M | ||
| Q4 24 | $215.7M | $199.9M | ||
| Q3 24 | $196.6M | $185.6M | ||
| Q2 24 | $198.6M | $177.5M |
净利润OFIXWK
| Q1 26 | — | $19.0M | ||
| Q4 25 | $-2.2M | $11.8M | ||
| Q3 25 | $-22.8M | $2.8M | ||
| Q2 25 | $-14.1M | $-19.4M | ||
| Q1 25 | $-53.1M | $-21.4M | ||
| Q4 24 | $-29.1M | $-8.8M | ||
| Q3 24 | $-27.4M | $-17.0M | ||
| Q2 24 | $-33.4M | $-17.5M |
毛利率OFIXWK
| Q1 26 | — | 80.4% | ||
| Q4 25 | 71.1% | 80.7% | ||
| Q3 25 | 72.2% | 79.3% | ||
| Q2 25 | 68.7% | 77.0% | ||
| Q1 25 | 62.8% | 76.6% | ||
| Q4 24 | 69.0% | 77.1% | ||
| Q3 24 | 68.7% | 76.5% | ||
| Q2 24 | 67.8% | 76.8% |
营业利润率OFIXWK
| Q1 26 | — | 25.8% | ||
| Q4 25 | 0.2% | 3.3% | ||
| Q3 25 | -8.3% | -1.5% | ||
| Q2 25 | -7.9% | -10.3% | ||
| Q1 25 | -25.2% | -12.0% | ||
| Q4 24 | -5.3% | -6.7% | ||
| Q3 24 | -9.6% | -11.7% | ||
| Q2 24 | -12.5% | -13.0% |
净利率OFIXWK
| Q1 26 | — | 7.7% | ||
| Q4 25 | -1.0% | 4.9% | ||
| Q3 25 | -11.1% | 1.2% | ||
| Q2 25 | -6.9% | -9.0% | ||
| Q1 25 | -27.4% | -10.4% | ||
| Q4 24 | -13.5% | -4.4% | ||
| Q3 24 | -13.9% | -9.2% | ||
| Q2 24 | -16.8% | -9.9% |
每股收益（稀释后）OFIXWK
| Q1 26 | — | $0.33 | ||
| Q4 25 | $-0.05 | $0.21 | ||
| Q3 25 | $-0.57 | $0.05 | ||
| Q2 25 | $-0.36 | $-0.35 | ||
| Q1 25 | $-1.35 | $-0.38 | ||
| Q4 24 | $-0.76 | $-0.15 | ||
| Q3 24 | $-0.71 | $-0.31 | ||
| Q2 24 | $-0.88 | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $334.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | — |
| 总资产 | $850.6M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXWK
| Q1 26 | — | $334.3M | ||
| Q4 25 | $82.0M | $338.8M | ||
| Q3 25 | $62.9M | $315.9M | ||
| Q2 25 | $65.6M | $284.3M | ||
| Q1 25 | $58.0M | $242.0M | ||
| Q4 24 | $83.2M | $301.8M | ||
| Q3 24 | $30.1M | $248.2M | ||
| Q2 24 | $26.4M | $267.9M |
总债务OFIXWK
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — |
股东权益OFIXWK
| Q1 26 | — | — | ||
| Q4 25 | $450.0M | $-5.4M | ||
| Q3 25 | $442.5M | $-36.9M | ||
| Q2 25 | $458.3M | $-66.5M | ||
| Q1 25 | $458.3M | $-75.7M | ||
| Q4 24 | $503.1M | $-41.7M | ||
| Q3 24 | $525.9M | $-50.8M | ||
| Q2 24 | $546.0M | $-77.7M |
总资产OFIXWK
| Q1 26 | — | $1.4B | ||
| Q4 25 | $850.6M | $1.5B | ||
| Q3 25 | $832.6M | $1.4B | ||
| Q2 25 | $837.2M | $1.3B | ||
| Q1 25 | $823.1M | $1.3B | ||
| Q4 24 | $893.3M | $1.4B | ||
| Q3 24 | $867.9M | $1.3B | ||
| Q2 24 | $882.0M | $1.2B |
负债/权益比OFIXWK
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $25.7M |
| 自由现金流率自由现金流/营收 | 7.6% | 10.4% |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $171.9M |
8季度趋势，按日历期对齐
经营现金流OFIXWK
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $51.0M | ||
| Q3 25 | $12.4M | $46.2M | ||
| Q2 25 | $11.6M | $50.3M | ||
| Q1 25 | $-18.4M | $-7.4M | ||
| Q4 24 | $23.7M | $44.0M | ||
| Q3 24 | $11.7M | $18.9M | ||
| Q2 24 | $9.0M | $-14.0K |
自由现金流OFIXWK
| Q1 26 | — | $25.7M | ||
| Q4 25 | $16.8M | $50.7M | ||
| Q3 25 | $2.5M | $46.1M | ||
| Q2 25 | $4.5M | $49.3M | ||
| Q1 25 | $-25.1M | $-8.1M | ||
| Q4 24 | $15.2M | $43.2M | ||
| Q3 24 | $6.3M | $18.7M | ||
| Q2 24 | $-360.0K | $-122.0K |
自由现金流率OFIXWK
| Q1 26 | — | 10.4% | ||
| Q4 25 | 7.6% | 21.2% | ||
| Q3 25 | 1.2% | 20.5% | ||
| Q2 25 | 2.2% | 22.9% | ||
| Q1 25 | -13.0% | -3.9% | ||
| Q4 24 | 7.0% | 21.6% | ||
| Q3 24 | 3.2% | 10.1% | ||
| Q2 24 | -0.2% | -0.1% |
资本支出强度OFIXWK
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 0.1% | ||
| Q3 25 | 4.8% | 0.0% | ||
| Q2 25 | 3.5% | 0.5% | ||
| Q1 25 | 3.5% | 0.4% | ||
| Q4 24 | 4.0% | 0.4% | ||
| Q3 24 | 2.7% | 0.1% | ||
| Q2 24 | 4.7% | 0.1% |
现金转化率OFIXWK
| Q1 26 | — | — | ||
| Q4 25 | — | 4.31× | ||
| Q3 25 | — | 16.57× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
WK
| Subscription and support | $225.4M | 91% |
| Other | $22.0M | 9% |
